Search results
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with...
Benzinga· 4 days agoFood and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment for adolescents ...
20210504 - CSMonitor.com
The Christian Science Monitor· 3 days agoOn Massachusetts’ Cape Cod, things are looking up for the Red Jacket Beach Resort and its sparkling Atlantic views. After a troubled year, the resort’s restaurants, swimming pools, deck chairs ...
NanoViricides Has Filed its Quarterly Report
The Sacramento Bee· 2 days agoSHELTON, CT / ACCESSWIRE / May 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that ...
Public school, religious instruction: How local charter students are getting religious schooling
U-T San Diego· 5 days agoIn San Diego County and across California, some K-12 school students are getting what their families...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 2 days agoSAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop ...
Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides...
WKRN Nashville· 2 days agoScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing ...
Cencora (NYSE:COR) Share Price Passes Above 200 Day Moving Average of $221.11
ETF DAILY NEWS· 12 hours agoCencora, Inc. (NYSE:COR – Get Free Report) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $221.11 and traded as high as ...
